Cargando…

Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association

BACKGROUND: The new European pharmacovigilance legislation has been suggested as marking the beginning of a new chapter in drug safety, making patients an important part of pharmacovigilance. In Sweden since 2008 it has been possible for consumers to report adverse drug reactions (ADRs) to the Medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilhelmsson, Andreas, Svensson, Tommy, Meeuwisse, Anna, Carlsten, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554467/
https://www.ncbi.nlm.nih.gov/pubmed/23259410
http://dx.doi.org/10.1186/2050-6511-13-19
_version_ 1782256897548615680
author Vilhelmsson, Andreas
Svensson, Tommy
Meeuwisse, Anna
Carlsten, Anders
author_facet Vilhelmsson, Andreas
Svensson, Tommy
Meeuwisse, Anna
Carlsten, Anders
author_sort Vilhelmsson, Andreas
collection PubMed
description BACKGROUND: The new European pharmacovigilance legislation has been suggested as marking the beginning of a new chapter in drug safety, making patients an important part of pharmacovigilance. In Sweden since 2008 it has been possible for consumers to report adverse drug reactions (ADRs) to the Medical Products Agency (MPA), and these reports are now understood as an increasingly valuable contribution in the monitoring of safety aspects in medicines. Already in 2002 it was possible to report experiences with medicines to the non-profit and independent organization Consumer Association for Medicines and Health (KILEN) through a web-based report form with an opportunity to describe ADR experiences in free text comments. The aim of this study was to qualitatively analyze the free text comments appended to consumer reports on antidepressant medication. METHODS: All reports of suspected adverse reactions regarding antidepressant medications submitted from January 2002 to April 2009 to KILEN’s Internet-based reporting system in Sweden were analyzed according to reported narrative experience(s). Content analysis was used to interpret the content of 181 reports with free text comments. RESULTS: Three main categories emerged from the analyzed data material: (1) Experiences of drug treatment with subcategories (a) Severe psychiatric adverse reactions, and (b) Discontinuation symptoms; (2) Lack of communication and (3) Trust and distrust. A majority of the reports to KILEN were from patients experiencing symptoms of mental disturbances (sometimes severe) affecting them in many different ways, especially during discontinuation. Several report included narratives of patients not receiving information of potential ADRs from their doctor, but also that there were no follow-ups of the treatment. Trust was highlighted as especially important and some patients reported losing confidence in their doctor when they were not believed about the suspected ADRs they experienced, making them attempt to discontinue their antidepressant treatment on their own. CONCLUSIONS: The present study indicates that free text comments as often contained in case reports directly submitted by patients can be of value in pharmacovigilance and provide important information on how a drug may affect the person using it and influence his or her personal life.
format Online
Article
Text
id pubmed-3554467
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35544672013-01-29 Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association Vilhelmsson, Andreas Svensson, Tommy Meeuwisse, Anna Carlsten, Anders BMC Pharmacol Toxicol Research Article BACKGROUND: The new European pharmacovigilance legislation has been suggested as marking the beginning of a new chapter in drug safety, making patients an important part of pharmacovigilance. In Sweden since 2008 it has been possible for consumers to report adverse drug reactions (ADRs) to the Medical Products Agency (MPA), and these reports are now understood as an increasingly valuable contribution in the monitoring of safety aspects in medicines. Already in 2002 it was possible to report experiences with medicines to the non-profit and independent organization Consumer Association for Medicines and Health (KILEN) through a web-based report form with an opportunity to describe ADR experiences in free text comments. The aim of this study was to qualitatively analyze the free text comments appended to consumer reports on antidepressant medication. METHODS: All reports of suspected adverse reactions regarding antidepressant medications submitted from January 2002 to April 2009 to KILEN’s Internet-based reporting system in Sweden were analyzed according to reported narrative experience(s). Content analysis was used to interpret the content of 181 reports with free text comments. RESULTS: Three main categories emerged from the analyzed data material: (1) Experiences of drug treatment with subcategories (a) Severe psychiatric adverse reactions, and (b) Discontinuation symptoms; (2) Lack of communication and (3) Trust and distrust. A majority of the reports to KILEN were from patients experiencing symptoms of mental disturbances (sometimes severe) affecting them in many different ways, especially during discontinuation. Several report included narratives of patients not receiving information of potential ADRs from their doctor, but also that there were no follow-ups of the treatment. Trust was highlighted as especially important and some patients reported losing confidence in their doctor when they were not believed about the suspected ADRs they experienced, making them attempt to discontinue their antidepressant treatment on their own. CONCLUSIONS: The present study indicates that free text comments as often contained in case reports directly submitted by patients can be of value in pharmacovigilance and provide important information on how a drug may affect the person using it and influence his or her personal life. BioMed Central 2012-12-23 /pmc/articles/PMC3554467/ /pubmed/23259410 http://dx.doi.org/10.1186/2050-6511-13-19 Text en Copyright ©2012 Vilhelmsson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vilhelmsson, Andreas
Svensson, Tommy
Meeuwisse, Anna
Carlsten, Anders
Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association
title Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association
title_full Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association
title_fullStr Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association
title_full_unstemmed Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association
title_short Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association
title_sort experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554467/
https://www.ncbi.nlm.nih.gov/pubmed/23259410
http://dx.doi.org/10.1186/2050-6511-13-19
work_keys_str_mv AT vilhelmssonandreas experiencesfromconsumerreportsonpsychiatricadversedrugreactionswithantidepressantmedicationaqualitativestudyofreportstoaconsumerassociation
AT svenssontommy experiencesfromconsumerreportsonpsychiatricadversedrugreactionswithantidepressantmedicationaqualitativestudyofreportstoaconsumerassociation
AT meeuwisseanna experiencesfromconsumerreportsonpsychiatricadversedrugreactionswithantidepressantmedicationaqualitativestudyofreportstoaconsumerassociation
AT carlstenanders experiencesfromconsumerreportsonpsychiatricadversedrugreactionswithantidepressantmedicationaqualitativestudyofreportstoaconsumerassociation